📋 Tender Overview
SLEEK enables high efficiency multi-transgene knock-in of induced Pluripotent Stem Cells iPSCs T cells and Natural Killer NK cellsData support SLEEK as an optimized approach to develop next generation cell therapy medicinesEditas Medicine Inc a leading genome editing company announced data on a new gene editing technology termed SLEEK SeLection by Essential-gene Exon Knock-in. The Company reported these data in an oral presentation at Cold Spring Harbor Laboratorys Genome Engineering CRISPR Frontiers meeting being held virtually August 18-20 2021.Despite major progress in achieving gene disruption efficient knock-in of transgenes continues to be a significant challenge for the gene editing field. To solve this challenge SLEEK was developed enabling high knock-in efficiencies with different transgenes while also ensuring robust transgene expression. Editas Medicine believes that SLEEK may enable the development of next generation cell therapeutics for cancer and other serious diseases.New preclinical data demonstrated that SLEEK results in the knock-in of multiple clinically relevant transgenes through a proprietary process that selects for cells containing the knock-in cargo. In addition high percentage knock-in efficiencies were enabled by Editas Medicines proprietary engineered AsCas12a nuclease. More than 90 percent knock-in efficiencies were observed in various clinically relevant target cells including iPSCs T cells and NK cells. Additionally SLEEK may be used to fine-tune the expression levels of transgene cargos an important attribute of next-generation cell therapy medicines.We find the new gene editing SLEEK technology to have immense potential as it enables nearly 100 percent knock-in of functional transgene cargos at specific locations in the genome which we believe to be the highest in the gene editing field across multiple cell types. We believe that this novel technology has broad applications and may result in substantially improved gene edited cell medicines including for novel CAR-T and CAR-NK cell therapies said Mark S. Shearman Ph.D. Executive Vice President and Chief Scientific Officer Editas Medicine. We believe SLEEK is an optimal approach to achieve highly efficient multi-transgene knock-in for the next generation of cell therapy medicines and we are leveraging this technology across many oncology programs including for treatment of a variety of solid tumors.In addition to the SLEEK oral presentation the Company also presented a poster on its CALITAS algorithm and software. CALITAS is a new state-of-the-art CRISPR-Cas tuned DNA aligner and is useful for the identification of potential off-target sites in silico.
